国际眼科纵览
國際眼科縱覽
국제안과종람
OREIGN MEDICAL SCIENCES
2015年
1期
34-38
,共5页
阿柏西普%血管内皮生长因子%新生血管形成
阿柏西普%血管內皮生長因子%新生血管形成
아백서보%혈관내피생장인자%신생혈관형성
Aflibercept%VEGF%neovascularization
眼底新生血管性疾病的预后主要取决于新生血管的形成情况.目前认为血管内皮生长因子(vascular endothelial growth factor,VEGF)是促新生血管生成最重要的诱导因子,也是抗新生血管治疗中重要的治疗靶点.阿柏西普是最新一代的抗VEGF药物,可以与VEGF-A、VEGF-B、血小板源性生长因子(platelet-derived growth factor,PDGF)所有亚型相结合,与VEGF有更高的亲和力,用于治疗湿性年龄相关性黄斑变性、视网膜静脉阻塞、糖尿病视网膜病变及息肉样脉络膜血管病变,能够提高患者最佳矫正视力和减少中央视网膜厚度,同时在某些其他抗VEGF无应答患者的治疗中亦获得较好效果.
眼底新生血管性疾病的預後主要取決于新生血管的形成情況.目前認為血管內皮生長因子(vascular endothelial growth factor,VEGF)是促新生血管生成最重要的誘導因子,也是抗新生血管治療中重要的治療靶點.阿柏西普是最新一代的抗VEGF藥物,可以與VEGF-A、VEGF-B、血小闆源性生長因子(platelet-derived growth factor,PDGF)所有亞型相結閤,與VEGF有更高的親和力,用于治療濕性年齡相關性黃斑變性、視網膜靜脈阻塞、糖尿病視網膜病變及息肉樣脈絡膜血管病變,能夠提高患者最佳矯正視力和減少中央視網膜厚度,同時在某些其他抗VEGF無應答患者的治療中亦穫得較好效果.
안저신생혈관성질병적예후주요취결우신생혈관적형성정황.목전인위혈관내피생장인자(vascular endothelial growth factor,VEGF)시촉신생혈관생성최중요적유도인자,야시항신생혈관치료중중요적치료파점.아백서보시최신일대적항VEGF약물,가이여VEGF-A、VEGF-B、혈소판원성생장인자(platelet-derived growth factor,PDGF)소유아형상결합,여VEGF유경고적친화력,용우치료습성년령상관성황반변성、시망막정맥조새、당뇨병시망막병변급식육양맥락막혈관병변,능구제고환자최가교정시력화감소중앙시망막후도,동시재모사기타항VEGF무응답환자적치료중역획득교호효과.
The prognosis of fundus neovascular diseases mainly depend on the situation of the neovascularization,vascular endothelial growth factor (VEGF) is considered to be the most important pathogenic factor,and also an important therapeutic target in fundus neovascular diseases.Aflibercept is the latest generation of anti-VEGF drugs,which binds VEGF-A and VEGF-B,as well as platelet-derived growth factor (PDGF),has higher affinity with VEGF.Aflibercept is applied to the treatment of wet age-related macular degeneration,retinal vein occlusion,diabetic retinopathy and polypoidal choroidal vasculopathy.It can improve the best corrected visual acuity and reduce the central retinal thickness.At the same time,in some non-response cases the good results are also received.
